DFTX
Definium Therapeutics Inc
$42.80
1.27 (2.89%) Today
0.17 (0.40%) After-hours
— up— down
Market Cap
$5.69B+343.6%
Revenue (TTM)
$0
$0Net Income (TTM)
$-427,194,251
$-427,194,251EPS (TTM)
-3.43
-3.43Shares Out
124.63M
124.63MOpen
$42.63
$42.63Previous Close
$43.90
$43.90Day Range
$42.01 – $43.74
$42.01 – $43.7452-Week Range
$8.70 – $49.70
$8.70 – $49.70Beta
2.22
2.22Earnings Date
Nov 4, 2026
Nov 4, 2026Volume
1.70M
1.70MAvg Volume
2.64M
2.64MAnalyst Rating
Buy
BuyExchange
NASDAQ NMS - GLOBAL MARKET
NASDAQ NMS - GLOBAL MARKETAbout DFTX
Definium Therapeutics, Inc., formerly known as MindMed, is a New York-based biotechnology company that is currently developing clinical and therapeutic applications for psychedelic and, more broadly, psychoplastogenic drugs.
Related
News
N/AN/AN/AN/AN/A
Jones Trading Maintains Buy on Definium Therapeutics, Raises Price Target to $90
Benzinga · 2d ago
Canaccord Genuity Maintains Buy on Definium Therapeutics, Raises Price Target to $64
Benzinga · 2d ago
RBC Capital Maintains Outperform on Definium Therapeutics, Raises Price Target to $66
Benzinga · 2d ago
Wells Fargo Maintains Overweight on Definium Therapeutics, Raises Price Target to $72
Benzinga · 2d ago
Baird Maintains Outperform on Definium Therapeutics, Raises Price Target to $75
Benzinga · 2d ago